Open AccessSecond line platinum‐based intraperitoneal chemotherapy for advanced ovarian cancer
Author(s) -
MILCZEK TOMASZ,
KLASAMAZURKIEWICZ DAGMARA,
EMERICH JANUSZ,
KOBIERSKI JULIUSZ
Publication year - 2009
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1080/00016340902777525
Subject(s) - medicine , carboplatin , ovarian cancer , regimen , laparotomy , cyclophosphamide , chemotherapy , surgery , cisplatin , progressive disease , cancer , oncology
Abstract Objective . To report the results of ovarian cancer treatment, where a regimen of intravenous cyclophosphamide followed by intraperitoneal cisplatin or carboplatin was administered as second line treatment. Design . Retrospective observational study on 198 women with stage I–IV histologically documented epithelial ovarian cancer after one or more prior regimens of chemotherapy. Setting . University tertiary referral clinic, Gdansk, Poland. Methods . The study group was recruited from among 593 ovarian cancer patients treated between January 1996 and December 2006. Conditions of inclusion for intraperitoneal treatment were: relapse or recurrence of disease after surgery followed by first line treatment. Recurrences were confirmed through re‐staging laparotomy or second‐look laparotomy. Patients received 90 mg/m 2 cisplatin, or carboplatin AUC 6 intraperitoneally and cyclophosphamide 750 mg/m 2 intravenously. Four or six courses were planned for each patient. Main outcome measures . Response to treatment defined as complete or partial response, or progressive disease, and survival rates. Results . There were 67 (34%) with complete and 61 (31%) with partial response, while 69 (35%) developed progressive disease. Median survival from the initiation of intraperitoneal chemotherapy (IP) was 51 months and significantly longer for patients who received four cycles of IP: 78 months vs. 20 months for patients who received six intraperitoneal cycles. Conclusions . IP can be used in second line treatment of ovarian cancer, but six treatment cycles appear associated with worse results compared to four.